University of North Carolina at Chapel Hill at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of North Carolina at Chapel Hill brings 3 presentations to ASH 2026 in New Orleans. Its program centres on targeted drugs for acute myeloid leukemia and on aging with sickle cell disease. It also covers menin inhibitors in AML, stroke and heart problems in older sickle cell patients, and wellness for medical educators.
| Organization | ASH 2026 Attendance |
|---|---|
University of North Carolina at Chapel Hill Chapel Hill, NC | |
Public research university in Chapel Hill, home to the UNC School of Medicine and Lineberger Comprehensive Cancer Center. | Session Targeted Therapies for AML: Bulls Eye! Menin inhibitors and other targeted drugs for acute myeloid leukemia, their use with frontline therapy, resistance to them and next-generation agents. Talk Targeted Therapy Approaches with Menin Inhibitors: Light at the End of the Tunnel? Menin inhibitors in relapsed acute myeloid leukemia, how resistance develops, and pairing them with azacitidine, venetoclax, or chemotherapy up front. Talk Stroke in the Older Adult with Sickle Cell Disease Treating stroke in older adults with sickle cell disease with transfusion first and clot-busting drugs when suitable, and gaps in preventing repeat strokes. Session The Heart and Brain in Older Patients with Sickle Cell Disease Heart disease, stroke, and cognitive decline in adults aging with sickle cell disease, and how heart ultrasound and other tools guide prevention and care. |
Instantly find 20 buyers from University of North Carolina at Chapel Hill
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction